CLINICAL TRIALS PROFILE FOR ATOMOXETINE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for atomoxetine hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00029614 ↗ | Atomoxetine to Treat Adolescents With Coexisting Alcohol and Other Substance Use Disorder and ADHD | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 2 | 2006-05-01 | The purpose of this study is to compare the effectiveness and safety of atomoxetine in the treatment of adolescents with coexisting alcohol or substance use disorders and Attention Deficit Hyperactivity Disorder (ADHD). |
| NCT00029614 ↗ | Atomoxetine to Treat Adolescents With Coexisting Alcohol and Other Substance Use Disorder and ADHD | Completed | University of Pittsburgh | Phase 2 | 2006-05-01 | The purpose of this study is to compare the effectiveness and safety of atomoxetine in the treatment of adolescents with coexisting alcohol or substance use disorders and Attention Deficit Hyperactivity Disorder (ADHD). |
| NCT00089869 ↗ | A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia | Completed | Eli Lilly and Company | Phase 1/Phase 2 | 1969-12-31 | Study of a medication for the treatment of Schizophrenia in patients who are already taking Abilify, Risperdal, Seroquel, Zyprexa |
| NCT00142961 ↗ | Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 2005-10-01 | Attention Deficit Hyperactivity Disorder (ADHD) is common among adolescents seeking treatment for marijuana dependence. The purpose of this study is to determine the use of atomoxetine in treating adolescents who abuse marijuana and have ADHD. In addition, this study will assess whether atomoxetine reduces ADHD symptoms as compared to a placebo. Finally, the study will determine whether atomoxetine improves treatment retention and progress in adolescents with ADHD and marijuana dependence. |
| NCT00142961 ↗ | Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder | Completed | New York State Psychiatric Institute | Phase 2 | 2005-10-01 | Attention Deficit Hyperactivity Disorder (ADHD) is common among adolescents seeking treatment for marijuana dependence. The purpose of this study is to determine the use of atomoxetine in treating adolescents who abuse marijuana and have ADHD. In addition, this study will assess whether atomoxetine reduces ADHD symptoms as compared to a placebo. Finally, the study will determine whether atomoxetine improves treatment retention and progress in adolescents with ADHD and marijuana dependence. |
| NCT00161031 ↗ | Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia | Completed | University of Maryland | N/A | 2004-04-01 | The purpose of this study is to: - To examine wether adjunctive atomoxetine is more effective thank placebo for neuropsychological measures of reaction time, motor speed, psychomotor speed, sustained attention, learning and memory, working memory, and executive functioning. To determine the effect size of atomoxetine on these neuropsychological measures for follow-up studies. - To determine if atomoxetine has short-term benefits for improving weight gain and other metabolic abnormalities associated with antipsychotics. |
| NCT00161031 ↗ | Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia | Completed | University of Maryland, Baltimore | N/A | 2004-04-01 | The purpose of this study is to: - To examine wether adjunctive atomoxetine is more effective thank placebo for neuropsychological measures of reaction time, motor speed, psychomotor speed, sustained attention, learning and memory, working memory, and executive functioning. To determine the effect size of atomoxetine on these neuropsychological measures for follow-up studies. - To determine if atomoxetine has short-term benefits for improving weight gain and other metabolic abnormalities associated with antipsychotics. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for atomoxetine hydrochloride
Condition Name
Clinical Trial Locations for atomoxetine hydrochloride
Trials by Country
Clinical Trial Progress for atomoxetine hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for atomoxetine hydrochloride
Sponsor Name
